Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average […]
More Stories
The Goldman Sachs Group Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $200.00
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $180.00 to...
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research report sent...
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a research report issued to...
Alerus Financial (NASDAQ:ALRS) Upgraded at Raymond James
Raymond James upgraded shares of Alerus Financial (NASDAQ:ALRS – Free Report) from a market perform rating to an outperform rating...
Sanford C. Bernstein Cuts Airbnb (NASDAQ:ABNB) Price Target to $155.00
Airbnb (NASDAQ:ABNB – Free Report) had its price target trimmed by Sanford C. Bernstein from $174.00 to $155.00 in a...
Waystar Holding Corp. (NASDAQ:WAY) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Waystar Holding Corp. (NASDAQ:WAY – Get Free Report) have been given a consensus rating of “Buy” by the...